Proportion and reasons for loss to follow-up in a cohort study of people who inject drugs to measure HIV and HCV incidence in Kerman, Iran

Ghazal Mousavian 1, Nima Ghalekhani 1, Fatemeh Tavakoli 1, Willi McFarland 2, Armita Shakesmaeili 1, Heidar Sharafi 1,3, Mehrdad Khezri 1, Soheil Mehmandoost 1, Jasem Zarei 1, Hamid Sharifi 1* and Ali Mirzazadeh 1,2

Abstract

Background: Understanding the reasons for loss to follow-up (LTFU) in cohort studies, especially among marginalized groups such as people who inject drugs (PWID), is needed to strengthen the rigor of efficacy trials for prevention and treatment interventions. We assessed the proportion and reasons for loss to follow-up in a recent cohort of PWID enrolled in the southeast of Iran.

Methods: Using respondent-driven sampling, we recruited 98 PWID age 18 years or older who reported injecting drugs in the past 6 months, and were negative for HIV and HCV at initial screening. Participants were followed at 6 week intervals, alternating a short six-week visit and long 12-week or quarterly visit to measure incidence of HIV and HCV. Methods to enhance retention included incentives for completing each visit, tracking people who missed the scheduled visits through their peer referral networks, engaged outreach teams to explore hotspots and residences, and photos. LTFU was defined as participants who missed their quarterly visits for 2 or more weeks.

Results: Mean (SD) age of participants was 39.7 years (SD 9.6). Of 98 enrolled, 50 participants (51.0%) were LTFU by missed their scheduled quarterly visits for 2 weeks or more. For those whose reasons for LTFU could be defined (46.0%, 23 of 50), main reasons were: forgetting the date of visit (43.5%, 10 of 23), being incarcerated (39.1%, 9 of 23), and moving out of the city (17.4%, 4 of 23).

Conclusion: This study highlighted the difficulty in retaining PWID in longitudinal studies. Despite having several retention strategies in place, over half of PWID were LTFU. The LTFU might be reduced by setting up more effective reminder systems, working closely with security systems, and online means to reach those who move outside the study area.

Keywords: Follow-up study, People who inject drugs, Loss to follow-up, Reminder system
Introduction

Injection drug use provides an efficient mechanism for transmitting blood-borne viruses and in many low and middle-income countries like Iran, transmission among people who inject drugs (PWID) has emerged as a contributor to hepatitis C virus (HCV) and HIV epidemics through the sharing of drug injection equipment [1, 7, 15]. These two infections are responsible for high morbidity and mortality among PWID globally [6]. Approximately 15.6 million people inject drugs worldwide [9], with an estimated 208,000 residing in Iran [18]. Also the recent studies showed the prevalence of HIV and HCV among PWID (HIV: 14.3% before 2007 and 9.7% after 2007, HCV: 45%) [14, 20] and people who use non-injection drugs (HIV: 5.4% after 2005, HCV: 8%) remains considerably higher than those in the general population [2].

While studies have been primarily limited to cross-sectional studies among this key population in Iran where injection drug use is a significant route of HIV transmission, cohort studies of PWID are required to assess causal pathways from risk factors to acquisition of infection and, perhaps more importantly, to demonstrate the efficacy of interventions to prevent infection [4]. Randomized controlled trials for HIV and HCV prevention, including vaccine studies, need to be established. Direct measures of HIV and HCV incidence are only possible in prospective cohort studies [10]. Moreover, observational, community-based cohort studies of PWID for evaluating HIV and HCV vulnerabilities are lacking in many developing countries with high numbers of PWID, including Iran.

Loss to follow-up (LTFU) of participants is a main concern for internal validity of cohort studies, especially among hard-to-reach populations like PWID. LTFU not only decreases the power of the study (i.e., the sample size decreases), but also could lead to participation bias (those who remained are different from those who are lost or censored). Reasons for LTFU in cohorts of PWID in international studies [12, 23] included factors relating to transportation, such as money for fares and far distances to the study site [8, 24]. As the reasons for LTFU could be different in different settings, studies on the reasons for LTFU are necessary in different locations.

To further improve our knowledge of barriers to retention of PWID for studies in Iran and possible extension to other areas of the Middle East, we characterize differences between PWID who were LTFU and those who remained in the early period of a cohort study in southeast of Iran.

Methods

Study design

This cohort study was conducted primarily to measure HIV and HCV incidence among PWID in Kerman city, located in the southeast of Iran. Participants were recruited from a parallel cross-sectional study that was used respondent-driven sampling (RDS) between July 10, 2018 and May 12, 2019. Eligibility criteria were: 1) injecting an illicit substance at least once in the last 6 months, 2) HIV and HCV antibody negative, 3) did not intend to travel from the city in the next 12 months, 4) being age 18 years or older, and 5) providing verbal consent. At baseline, participants were tested for HIV and HCV antibodies using rapid tests (SD BIOLINE HIV-1/2 3.0 and SD BIOLINE HCV). Reactive results for HIV and HCV were confirmed with fourth-generation enzyme-linked immunosorbent assay (ELISA) and reverse transcription- polymerase chain reaction (RT-PCR), respectively. Participants who confirmed to have HIV were referred to a voluntary counselling and testing (VCT) centre which facilitated their linkage to care. Participant who confirmed to have HCV were enrolled into a single-arm clinical trial for HCV care and treatment. HCV and HIV non-infected participants and those with sustained virologic response from the clinical trial arm were included in the cohort study to measure the incidence of these two infections.

Data collection instrument

Demographic and risk behavioral data were collected using a face-to-face interview with two trained gender-matched interviewers in a private room. At the first visit, we used a bio-behavioral questionnaire which consisted of 14 sections, including socio-demographic characteristics, history of non-injection drug and alcohol use, smoking history, history of drug injection, history of addiction treatment, sexual risk behaviors, access and use of prevention programs, awareness of HIV transmission and prevention, HIV testing, awareness of HCV transmission and prevention, and mental health. A short questionnaire was used to update their behaviors in the past 3 months in follow-up interviews.

Follow-up procedures and LTFU definition

Participants enrolled agreed to come to the study site at intervals of 6 weeks for almost 12 months. The first appointment was a short visit and with collection of 10 ml of blood for storage. The alternating quarterly appointments included a questionnaire measuring their behaviors during the last 12 weeks, in addition to collection of 10 ml of blood for storage and repeat rapid tests for HIV and HCV. Participants were received an additional $2.5 USD for completing short appointments and $6 USD for quarterly appointments. If participants missed their scheduled quarterly visits for 2 weeks or more, they were classified as LTFU. To mitigate LTFU, we engaged an outreach team familiar with hotspots and the registered addresses of the participants to find them and refer
them to the study site. The outreach team, about 3 days before the scheduled visit, used a photo and phone number of the participants who had consented to use to assist with locating the participants. Further, we used the network of participants who were linked to recruitment to attempt re-contact (i.e., contact through their original recruiter or recruits). To measure reasons for LTFU, we included an additional interview using a structured questionnaire whenever people who missed the scheduled visits returned to the study site, or when reached through their networks or by the outreach team.

**Analysis**

Data were collected using Research Electronic Data Capture (REDCap) software and were analyzed using Microsoft Excel 2013 and Stata 14.1 (StataCorp). Descriptive statistics characterized demographic and clinical information and tracing the history of participants who were LTFU. We used independent t-test and chi-square tests to examine associations between independent variables and LTFU status.

**Results**

A total of 167 eligible PWID were screened at the baseline visit. Of these, 98 agreed to participate in the cohort study (Fig. 1). The majority of participants were male (85.7%), 30 years of age or older (85.8%), ever experienced being homeless (91.8%), had some or completed secondary or high school education (543.1%), were not living with a spouse or partner (85.8%), employed (76.5%), and had a monthly income less than $100 (66.3%). While the majority had injected drugs with another person in the last 12 months (64.2%), sharing injecting equipment (8.1%) or syringes (6.1%) were low. Ever experiencing overdose was reported by (41.9%).

Of the 98 recruited PWID, 50 (51.0%; 95% confidence intervals (CIs): 38.1, 59.1) were LTFU. There was no significant difference between those who remained in the study and those who LTFU on any of the above variables apart from age (Table 1). Compared to those retained in the cohort, those LTFU were younger age (39.75 ± 9.64

![Fig. 1 Reasons for LTFU in a cohort study among PWID in Kerman, Iran](image-url)
| Characteristics                           | Total (N = 98) | Lost to Follow-up (N = 50) | Retained in the cohort (N = 48) | P-Value |
|------------------------------------------|----------------|---------------------------|--------------------------------|---------|
| **Sex**                                  |                |                           |                                |         |
| Female                                   | 14 (14.3%)     | 6 (12.0%)                 | 8 (16.7%)                      | 0.509   |
| Male                                     | 84 (85.7%)     | 44 (88.0%)                | 40 (83.3%)                     |         |
| **Age**                                  |                |                           |                                |         |
| Mean ± SD                                | 39.75 ± 9.64   | 37.96 ± 8.86              | 41.79 ± 10.14                  | 0.049   |
| **Ever homeless**                        |                |                           |                                |         |
| No                                       | 8 (8.2%)       | 4 (8.0%)                  | 4 (8.5%)                       | 0.927   |
| Yes                                      | 90 (91.8%)     | 46 (92.0%)                | 43 (91.5%)                     |         |
| **Education**                            |                |                           |                                |         |
| Primary or less                          | 37 (37.8%)     | 18 (36.0%)                | 19 (39.6%)                     | 0.619   |
| Some or completed secondary or high school | 53 (54.1%)   | 29 (58.0%)                | 24 (50.0%)                     |         |
| University                               | 8 (8.1%)       | 3 (6.0%)                  | 5 (10.4%)                      |         |
| **Living with their spouse/partner**     |                |                           |                                |         |
| Yes (i.e., married, live with partners)  | 14 (14.2%)     | 8 (16.0%)                 | 6 (12.5%)                      | 0.621   |
| No (i.e., single, married but live alone, widowed) | 84 (85.8%) | 42 (84.0%)              | 42 (87.5%)                     |         |
| **Job Status**                           |                |                           |                                |         |
| Unemployed                               | 23 (23.5%)     | 10 (20.0%)                | 13 (27.1%)                     | 0.408   |
| Employed                                 | 75 (76.5%)     | 40 (80.0%)                | 35 (72.9%)                     |         |
| **Monthly income**                       |                |                           |                                |         |
| Under 1,000,000 T (<$100)                | 65 (66.3%)     | 34 (68.0%)                | 31 (64.6%)                     | 0.303   |
| 1,000,000-4,999,999 T ($100–499)         | 31 (31.6%)     | 14 (28.0%)                | 17 (35.4%)                     |         |
| 5,000,000 T or more (> $500)             | 2 (2.1%)       | 2 (4.0%)                  | 0                              |         |
| **Alcohol use in the last 12 months**    |                |                           |                                |         |
| No                                       | 77 (79.4%)     | 36 (73.5%)                | 40 (85.1%)                     | 0.160   |
| Yes                                      | 20 (20.6%)     | 13 (26.5%)                | 7 (14.9%)                      |         |
| **Injecting frequency reported in the last 3 months** | | | | |
| No recent injection                      | 15 (15.3%)     | 11 (22.5%)                | 4 (8.3%)                       | 0.160   |
| < weekly                                 | 34 (34.7%)     | 16 (32.6%)                | 18 (37.5%)                     |         |
| < not daily but at least weekly (i.e., weekly) | 22 (22.5%) | 8 (16.3%)              | 14 (29.2%)                     |         |
| Daily                                    | 27 (27.5%)     | 14 (28.6%)                | 12 (25.0%)                     |         |
| **Injected with another person in the last 12 months** | | | | |
| No                                       | 35 (35.8%)     | 18 (36.0%)                | 17 (36.2%)                     | 0.986   |
| Yes                                      | 63 (64.2%)     | 32 (64.0%)                | 30 (63.8%)                     |         |
| **Receptive injecting equipment sharing in the last 12 months** | | | | |
| No                                       | 90 (91.9%)     | 44 (88.0%)                | 46 (95.8%)                     | 0.157   |
| Yes                                      | 8 (8.1%)       | 6 (12.0%)                 | 2 (4.2%)                       |         |
| **Receptive syringe sharing in the last 12 months** | | | | |
| No                                       | 92 (93.9%)     | 46 (92.0%)                | 46 (95.8%)                     | 0.429   |
| Yes                                      | 6 (6.1%)       | 4 (8.0%)                  | 2 (4.2%)                       |         |
| **Ever history of drug overdose**        |                |                           |                                |         |
| No                                       | 57 (58.1%)     | 26 (52.0%)                | 31 (64.6%)                     | 0.207   |
| Yes                                      | 41 (41.9%)     | 24 (48.0%)                | 17 (35.4%)                     |         |
vs. $37.96 \pm 8.86$ years, $p = 0.049$). Of the 50 LTFU we attempted to locate by all methods, we could not contact 26 persons (52.0%). One person (2%) had died. Among the 23 persons who we contacted, nine (39.1%) were incarcerated, four (17.4%) moved to another city, and ten (43.5%) said that they forgot the appointment date (Fig. 1).

While there were some suggested differences, we did not find significant difference in demographic and behaviors of those who were LTFU and found later compared to those who we could not find (Table 2).

**Discussion**

This study highlighted the difficulty of retaining PWID in a longitudinal study in Iran. Despite having several retention strategies, more than half of PWID missed their quarterly follow-up visit. The level of loss to follow-up in our study was higher than other studies. For example, one study of HIV incidence and factors contributing to retention in a 12-month follow-up study of PWID in Sichuan Province, China reported a retention rate of 70% [22]. Another study on HIV incidence and behavioral correlates of HIV acquisition among PWID in St Petersburg, Russia reported a retention rate of 80% [13].

Forgetting the date of visit, moved to another city, and incarceration, lack of transportation, distance, transfer to other similar studies with different objectives, financial constraints, and improving or deteriorating health were common reasons for not returning to study sites elsewhere [5, 8, 16]. Also, in the study of Weigel et al., out of 11,827 Patients who were lost to follow-up, 9432 (79.7%) had transferred to another clinic [25]. Our incentives attempted to pay a reasonable financial incentive to compensate for the expenses of participation and transportation costs. To reduce the LTFU, we tried to establish the study site in an easy-access place for the participants and the time for visiting was wide. Participants could attend the follow-up visits for 2 weeks (each week two possible visits) after their scheduled visit. Moreover, before running the study, we conducted a qualitative study to measure how we could reduce LTFU. Understanding the reasons for LTFU could help manage to reduce LTFU [17]. One challenge noted in the formative and follow-up phases was the likelihood of being detained and incarcerated. Among our study participants who missed their visits, over 40% were in prison. Alternatives to prison, such as sending PWID to drug abstinence camps, are being considered to decrease harm related to drugs [17]. Such solutions may also be more amenable to study participation follow-up.

Similar to other communities and countries, illicit drug use and users experience stigma and discrimination, having negative impact drug user’s mental and physical health. However, the stigmatization is not equal; studies showed that the use of a given substance is more stigmatized if it is injected rather than being inhaled or smoked [19, 21].

Similar to findings of other studies, we found that PWID may have experienced stigma and discrimination for injecting drugs by others or even among themselves, which decrease their willingness to seek for services or attending a study targeted for people who inject drugs that requires multiple visits. Any kind of link to such targeted services or studies may put them at risk of unwanted disclosure of their injecting drug status. They were also afraid that they would be arrested by police or that their families would find out that they inject drugs. In line with Arndt who mentioned that “There is no good reason to continue to support science built on this unintentional stereotyping”, we believe that strong evidences are need for proving our finding and we will consider this for our future studies [3]. To address these barriers, we should reduce stigma through education and awareness programs, using peer workers in research among PWID [17].

Although more than half of the participants were LTFU, there were no significant differences between LTFU and retained participants apart from age. Addressing LTFU is essential in two aspects. First, it will reduce the study’s power when the number of people who are missed is high. Second, this leads to participation bias, when those retained in a study differ from those who missed are different (informative censoring). The results of this study suggest that the LTFU would not greatly alter the risk profile of the cohort. When the missing is non-informative, the risk of participation bias is not a considerable concern. When the characteristics of those who retained in the study are the same as those who LTFU, the average outcome in the LTFU participants is the same as the average outcome in the retained participants. In these situations, we could estimate the parameters in LTFU participants and then in the whole population using some methods like inverse probability weighting [11].

This study has several limitations. First, the study’s sample size was small; therefore, the analysis may not have had enough power to detect smaller differences between those who retained and those who were LTFU. Second, behavioral data and the reasons for LTFU were self-reported. Some participants may not disclose their behaviors or reasons for LTFU due to participation bias and social acceptability bias. Third, we could not find the reasons for LTFU among more than half of the censored participants. Their reasons for lost to follow-up were therefore not known. Incorrect or missing telephone numbers and addresses were often the main reason why our team could not find them. Although our study had an outreach team that routinely tried to contact participants in hotspots, street locations, and other public spaces, the majority of participants who were LTFU could not be found.
Table 2: Demographic and behavior characteristics of people who inject drugs who loss to follow-up from a cohort study in Kerman, Iran

| Characteristics                        | Total LTFU (N = 50) | Not found (N = 27) | Later Found (N = 23) | P-Value |
|----------------------------------------|---------------------|--------------------|----------------------|---------|
| **Sex**                                |                     |                    |                      |         |
| Female                                 | 6 (12.0%)           | 2 (7.4%)           | 4 (17.4%)            |         |
| Male                                   | 44 (88.0%)          | 25 (92.6%)         | 19 (82.6%)           | 0.279   |
| **Age**                                |                     |                    |                      |         |
| Mean ± SD                              | 37.96 ± 8.86        | 39.59 ± 9.43       | 36.04 ± 7.91         | 0.719   |
| **Ever homeless**                      |                     |                    |                      |         |
| No                                     | 4 (8.0%)            | 1 (3.7%)           | 3 (13.1%)            | 0.225   |
| Yes                                    | 46 (92.0%)          | 26 (96.3%)         | 20 (86.9%)           |         |
| **Education**                          |                     |                    |                      |         |
| Primary or less                        | 18 (36.0%)          | 11 (40.7%)         | 7 (30.5%)            | 0.624   |
| Some or completed high school          | 29 (58.0%)          | 14 (51.9%)         | 15 (65.2%)           |         |
| University                             | 3 (6.0%)            | 2 (7.4%)           | 1 (4.3%)             |         |
| **Living with their spouse/partner**   |                     |                    |                      |         |
| Yes (i.e., married, live with partners)| 8 (16.0%)           | 6 (22.2%)          | 2 (8.7%)             | 0.193   |
| No (i.e., single, married but live alone, widowed) | 42 (84.0%) | 21 (77.8%) | 21 (91.3%) |         |
| **Job Status**                         |                     |                    |                      |         |
| Unemployed                             | 10 (20.0%)          | 5 (18.5%)          | 5 (21.7%)            | 0.777   |
| Employed                               | 40 (80.0%)          | 22 (81.5%)         | 18 (78.3%)           |         |
| **Monthly income**                     |                     |                    |                      |         |
| Under 1,000,000 T (<$100)              | 34 (68.0%)          | 20 (74.1%)         | 14 (60.8%)           | 0.252   |
| 1,000,000-4,999,999 T ($100–499)       | 14 (28.0%)          | 7 (25.9%)          | 7 (30.4%)            |         |
| 5,000,000 T or more (> $500)           | 2 (4.0%)            | 0                  | 2 (8.8%)             |         |
| **Alcohol use in the last 12 months**  |                     |                    |                      |         |
| No                                     | 36 (73.5%)          | 19 (70.4%)         | 17 (77.3%)           | 0.586   |
| Yes                                    | 13 (26.5%)          | 8 (29.6%)          | 5 (22.7%)            |         |
| **Injecting frequency reported in the last 3 months** |                     |                    |                      |         |
| No recent injection                    | 11 (22.5%)          | 7 (25.9%)          | 4 (18.2%)            | 0.291   |
| < weekly                               | 16 (32.6%)          | 9 (33.4%)          | 7 (31.8%)            |         |
| < not daily but at least weekly (i.e., weekly) | 8 (16.3%) | 6 (22.2%) | 2 (9.1%) |         |
| Daily                                  | 14 (28.6%)          | 5 (18.5%)          | 9 (40.9%)            |         |
| **Injected with another person in the last 12 months** |                     |                    |                      |         |
| No                                     | 18 (36.0%)          | 7 (25.9%)          | 11 (47.8%)           | 0.108   |
| Yes                                    | 32 (64.0%)          | 20 (74.1%)         | 12 (52.2%)           |         |
| **Receptive injecting equipment sharing in the last 12 months** |                     |                    |                      |         |
| No                                     | 44 (88.0%)          | 24 (88.9%)         | 20 (87.0%)           | 0.834   |
| Yes                                    | 6 (12.0%)           | 3 (11.1%)          | 3 (13.0%)            |         |
| **Receptive syringe sharing in the last 12 months** |                     |                    |                      |         |
| No                                     | 46 (92.0%)          | 26 (96.3%)         | 20 (87.0%)           | 0.225   |
| Yes                                    | 4 (8.0%)            | 1 (3.7%)           | 3 (13.0%)            |         |
| **Ever history of drug overdose**      |                     |                    |                      |         |
| No                                     | 26 (52.0%)          | 14 (51.8%)         | 12 (52.2%)           | 0.982   |
| Yes                                    | 24 (48.0%)          | 13 (48.2%)         | 11 (47.8%)           |         |
Conclusions

Despite limitations, this research is the first study in Iran to describe the reasons for LTFU of PWID in a cohort study. Also, it should be noted that the comprehensive formative assessment for evaluating the feasibility of conducting studies in a similar context like Iran is essential. We found the number of participants who missed their appointments was considerable, although differences between those LTFU and retained were not substantial. Improving reminder systems, working with prison organizations, recruiting people who have no definite plan to travel, and online means to contact those who do move are likely to improve retention in PWID population cohort studies.

Abbreviations

LTFU: Loss to Follow Up; HIV: Human Immunodeficiency Virus; HCV: Hepatitis C Virus; SD: Standard Deviation; PWID: People Who Inject Drugs; RDS: Respondent-Driven Sampling; ELISA: Enzyme-Linked Immunosorbent Assay; RT-PCR: Transcription- Polymerase Chain Reaction; VCT: Voluntary Counselling and Testing; REDCap: Research Electronic Data Capture; NIMA D: National Institute for Medical Research Development; ITAPS: International Traineeships in AIDS Prevention Studies

Acknowledgements

This research was supported by a grant from the National Institutes of Health, University of California, San Francisco-Gladstone Institute of Virology & Immunology Center for AIDS Research (P30-A10277635), AIDS Research Institute Strategic Support, the Iranian Ministry of Health (Mental Health and HIV national program), and National Institute for Medical Research Development (NIMAD). We also wish to acknowledge the support from the University of California, San Francisco’s International Traineeships in AIDS Prevention Studies (ITAPS), U.S. NIMH, R25 MH064712.

Authors’ contributions

Hamid Sharifi, Ali Mirzazadeh and Armita Shahezmaeeli designed and directed the project. Ghazal Mousavian, Nima Ghalekhani, Mehrdad Khezri, Soheil Mehmoodanto, Jasem Zarei and Fatemeh Tavakoli collected the data. Ghazal Mousavian, Nima Ghalekhani and Willi McFarland and Heidar Sharafi have contributed by leading the study design. Ghazal Mousavian and Nima Ghalekhani drafted the manuscript also Ghazal Mousavian analysed the data. Hamid Sharifi and Ali Mirzazadeh were supervised the work and data analysis. All authors discussed the results and commented on the manuscript. The author(s) read and approved the final manuscript.

Funding

This research was supported by a grant from the National Institutes of Health, University of California, San Francisco-Gladstone Institute of Virology & Immunology Center for AIDS Research (P30-A10277635), AIDS Research Institute Strategic Support, the Iranian Ministry of Health (Mental Health and HIV national program), and National Institute for Medical Research Development (NIMAD) (Grant Number# 973382).

Availability of data and materials

Data are available on request due to privacy or other restrictions.

Declarations

Ethics approval and consent to participate

All participants verbally consented to participate in this study, including the interview, HIV and HCV testing, storage of specimens, use of photos, and contact information. PWID who were diagnosed with HIV or HCV at baseline or during follow-up visits were referred to other study or programs for treatment services. The ethical committee of Kerman University of Medical Sciences approved the study protocol (IR#I KMUMREC.1396.2422), and University of California San Francisco (IRB # 16-18626) approved the study protocol.

Consent for publication

Participants have consented for publication.

Competing interests

The author have confirmed they have no potential competing interests to declare.

Author details

1HIV/STI Surveillance Research Center, and WHO Collaborating Center for HIV Surveillance, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, Iran. 2Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA, USA. 3Middle East Liver Diseases (MELD) Center, Tehran, Iran.

Accepted: 23 March 2021

Published online: 01 April 2021

References

1. Alter MJ, Moyer LA. The importance of preventing hepatitis C virus infection among injection drug users in the United States. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18(Suppl 1):S6–10. https://doi.org/10.1097/00002560-199802000-00003.

2. Amin-Esmaeili M, Rahimi-Movaghar A, Haghdoost, A.-a., & Mohraz, M. Evidence of HIV epidemics among non-injecting drug users in Iran: a systematic review. Addiction. 2012;107(11):1929–38. https://doi.org/10.1111/j.1360-0443.2012.03926.x.

3. Arndt S. Stereotyping and the treatment of missing data for drug and alcohol clinical trials. Subs Abuse Treat, Prev Policy. 2009;4(1):2–2. https://doi.org/10.1186/1747-597X-4-2.

4. Aye NS, Oo MM, Harries AD, Mon MM, Hone S, Oo HN, et al. HIV, HBV and HCV in people who inject drugs and are placed on methadone maintenance therapy, Yangon, Myanmar. Public Health Action. 2018;8(4): 202–10. https://doi.org/10.15588/pha.1800250.

5. Brinkhov MW, Pujades-Rodriguez M, Egger M. Mortality of patients lost to follow-up in antiretroviral treatment programmes in resource-limited settings: systematic review and meta-analysis. PloS One. 2009;4(6):e5790. https://doi.org/10.1371/journal.pone.0005790.

6. Coutinho RA, HIV and hepatitis C among injecting drug users: success in preventing HIV has not been mirrored for hepatitis C. Br Med J. 1998;317: 424–S. https://doi.org/10.1136/bmj.317.7156.424.

7. Coutinho R, Goudsmit J. Prevalence and risk factors of HIV infections among drug users and drug-using prostitutes in Amsterdam. AIDS (London, England). 1988;2(1):155–60. https://doi.org/10.1097/00002030-198802000-00010.

8. Dalal RP, MacPhail C, Mphayi M, Wing J, Feldman C, Cherish MF, et al. Characteristics and outcomes of adult patients lost to follow-up at an antiretroviral treatment clinic in Johannesburg, South Africa. JAIDS J Acq Immune Def Syndr. 2008;47(1):101–7. https://doi.org/10.1097/QAI.0b013e31815bb83a.

9. Degenhardt L, Peacock A, Collodge S, Leung J, Grebely J, Vickerman P, et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. Lancet Glob Health. 2017;5(12): e192–207. https://doi.org/10.1016/s2214-109x(17)30375-3.

10. Deschamps MM, Metch B, Morgan CA, Zorrilla CD, Donatony Y, Swann E, et al. Feasibility of identifying a female sex worker cohort at high risk of HIV infection in the Caribbean for HIV vaccine efficacy trials: longitudinal results of HVNT 907. J Acquir Immune Defic Syndr (1999). 2016;71(10):70–7. https://doi.org/10.1097/QAI.0000000000001796.

11. Hernán MA, Robins JM. Causal inference: what if. Boca Raton: Chapman & Hall/CRC; 2020.

12. Horyniak D, Higgs P, Jenkinson R, Degenhardt L, Stooël M, Kerr T, et al. Establishing the Melbourne Injecting Drug User Cohort Study (MIX): rationale, methods, and baseline and twelve-month follow-up results. Harm Reduct J. 2013;10(1):11. https://doi.org/10.1186/1477-7517-10-11.

13. Kozlov AP, Skochilov RV, Toussova O V, Verevochkin SV, Krasnoselskikh 3Middle East Liver Diseases (MELD) Center, Tehran, Iran.

14. https://doi.org/10.1097/md. 00000000000005238.
14. Malekinejad M, Navadeh S, Lotfizadeh A, Rahimi-Movahghar A, Amin-Emamnejad M, Norooz A. High hepatitis C virus prevalence among drug users in Iran: a systematic review and meta-analysis of epidemiological evidence (2001–2012). Int J Infect Dis. 2015;40:116–30. https://doi.org/10.1016/j.ijid.2015.09.022.

15. Martin NK, Vickereman P, Dore GJ, Hickman M. The hepatitis C virus epidemics in key populations (including people who inject drugs, prisoners and MSM): the use of direct-acting antivirals as treatment for prevention. Curr Opin HIV AIDS. 2015;10(5):374–80. https://doi.org/10.1097/COH.0000000000000179.

16. Miller CM, Kethlhapile M, Rybasack-Smith H, Rosen S. Why are antiretroviral treatment patients lost to follow-up? A qualitative study from South Africa. Tropical Med Int Health. 2010;15:48–54. https://doi.org/10.1111/j.1365-3156.2010.02514.x.

17. Mirzazadeh A, Hosseini-Hooshyar S, Shahesmaeili A, Bahramnejad A, Barshan A, Mousavian G, et al. Barriers and motivators to participation and retention in HIV/HCV cohort studies among people who inject drugs: a community consultation in Iran. Subst Abuse Treat Prev Policy. 2020;15(1):1–12. https://doi.org/10.1186/s13011-020-00298-y.

18. Nikfarjam A, Shokoohi M, Shahesmaeili A, Haghdoot AA, Baneshi MR, Haji-Maghsoodi S, et al. National population size estimation of illicit drug users through the network scale-up method in 2013 in Iran. Int J Drug Policy. 2016;31:147–52. https://doi.org/10.1016/j.drugpo.2016.01.013.

19. Paquette CE, Syvertsen JL, Pollini RA. Stigma at every turn: health services experiences among people who inject drugs. Int J Drug Policy. 2018;57:104–10. https://doi.org/10.1016/j.drugpo.2018.04.004.

20. Rahimi J, Gholami J, Amin-Emamnejad M, Fotouhi A, Rafieanesh H, Shadloo B, et al. HIV prevalence among people who inject drugs (PWID) and related factors in Iran: a systematic review, meta-analysis and trend analysis. Addiction. 2020;115(4):605–22. https://doi.org/10.1111/add.14853.

21. Rivera AV, DeCuir J, Crawford ND, Amesty S, Lewis CF. Internalized stigma and sterile syringe use among people who inject drugs in New York City, 2010–2012. Drug Alcohol Depend. 2014;144:259–64. https://doi.org/10.1016/j.drugalcdep.2014.09.078.

22. Ruan Y, Qin G, Liu S, Qian H, Zhang L, Zhou F, et al. HIV incidence and factors contributed to retention in a 12-month follow-up study of injection drug users in Sichuan Province, China. J Acquir Immune Defic Syndr. 2005;39(4):459–63. https://doi.org/10.1097/01.qai.0000152398.4702S.0F.

23. Rusheh-Escudero H, Vu A, Wirtz AL, Familiar-Lopez J, Berry M, Mbachio I, et al. Cross-sectional assessments of participants’ characteristics and loss to follow-up in the first opioid substitution therapy pilot program in Kabul, Afghanistan. Harm Reduct J. 2015;12(1):28. https://doi.org/10.1186/s12954-015-0062-1.

24. Tawaya H, Gupsa S, Hosseinipour M, Speight C, Ng’ambi W, Bokosi M, et al. Understanding factors, outcomes and reasons for loss to follow-Up among women in D ption B+ PMTCT programme in L llongwe, M alawi. Tropical Med Int Health. 2014;19(11):1360–6. https://doi.org/10.1111/tmi.12369.

25. Weigel R, Estill J, Egger M, Harries AD, Makombe S, Tawaya H, et al. Mortality and loss to follow-up in the first year of ART: Malawi national ART programme. AIDS (London, England). 2012;26(3):365–73. https://doi.org/10.1097/QAD.0b013e32834ed814.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.